The mission of the European Society of Cardiology (ESC) is to improve the quality of life of the European population by reducing the impact of cardiovascular disease. 1 The society has 45 000 members and holds an annual international congress, which is one of the leading events in cardiology each year. The interests of the 18 300 attendees spanned all areas of cardiology, such as arrhythmia and pacing, heart failure, ischaemia, cardiovascular interventions, epidemiology, hypertension, and basic science. The organisers received a record number of abstract submissions, accepting 2667 abstracts from the 9028 submitted. The main focus for the 2005 congress was cardiovascular health in women, a core activity related to the society's 'Women at Heart' project.
Women at Heart
Cardiovascular disease is the cause of nearly half of all deaths in Europe. In Europe, coronary heart disease remains the leading cause of death in men over 45 years and in women over 65 years. Overall, cardiovascular disease is estimated to cost the European Union economy 169 billion euro each year.
The 'Women at Heart' initiative 2 was launched in March 2005; it is aimed at medical professionals and committed to improving heart health in women. The initiative was launched to highlight the growing burden and under-appreciation of women's heart disease and to promote improved handling of women at risk of cardiovascular disease in clinical practice.
Cardiovascular disease is the primary cause of death in European women; it kills a higher percentage of women (55%) than men (43%) and more than the total deaths for all cancers combined. Cardiovascular disease is usually seen as a male disease and the underestimation of the impact of cardiovascular disease in women is not confined to the public. There is a disturbing gap in knowledge, understanding, and general awareness of cardiovascular disease in women, not only among women themselves, but also among medical practitioners. Women with heart disease tend to get heart disease later than men due to the cardioprotective effects of oestrogen, which plays an important role until menopause. After menopause, the risks increase significantly and need to be prevented and effectively managed.
In women, the onset of heart disease is more gradual, accompanied by fatigue, rather than the more commonly recognised symptoms, such as violent chest pain, that predominate in men. Since women's symptoms and disease progression trends differ from those experienced by men, primary-care physicians and cardiologists are frequently under-diagnosing and under-treating women since they are not sufficiently familiar with the less traditional presentation profiles. The chairperson of one of the sessions on women's health stated that women need to complain more since they often do not protest when their physician does not recognise their distress. After a diagnosis is made, women are being treated as if they are men, despite the notable differences in their disease.
The death of one out of every three women worldwide is caused by cardiovascular disease. In addition, stroke causes nearly 3 million deaths each year worldwide in women. Furthermore, women with cardiovascular disease are more likely to die or experience disability from recurrent attack or heart failure. Women are more likely than men to die of stroke. After a first stroke, women are kept in hospital longer and remain more disabled than men receiving similar care.
Women are not sufficiently represented in clinical trials and their cardiovascular disease clinical manifestations are less well outlined to the medical professional in their initial or further training. The percentage of women in randomised clinical trials ranges between 15% and 25%. There is much to be done to increase the understanding of cardiovascular disease in women and improve the quality of treatment of European women with cardiovascular disease.
An article in the ESC journal reviewed female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. [1] 
Initial Treatment of Chronic Heart Failure
Chronic heart failure is a vast, common, growing, and fatal condition and has considerable healthcare costs. It is estimated that, worldwide, 22 million people have chronic heart failure. It is the only major cardiovascular disease that is increasing in incidence.
The prevalence and mortality from chronic heart failure will rise with the ageing of the world's population and as more effective medical and surgical interventions tackle premature death from coronary artery disease, hypertension, and other cardiac conditions.
The risk of sudden death in people with heart failure is five times that of the general population of the same age.
The direct cost of heart failure in western industrialised nations is between 1% and 3% of total healthcare expenditure (i.e. 716 million euro each year).
There is an urgent need for the development of new therapeutic approaches to chronic heart failure. The primary goal of therapy is to increase survival.
Start with Bisoprolol or with Enalapril?
Administration of ACE inhibitors has been shown to delay the progression of heart failure and to improve clinical outcomes. Administration of β-blockers has further reduced mortality and morbidity, and has proven to be important for the treatment of patients with heart failure. Current guidelines from the European Society of Cardiology, American College of Cardiology, and American Heart Association recommend that heart failure treatment should be started with an ACE inhibitor and that a β-blocker should be added after administration of the initial ACE inhibitor. The sequence of initiating these agents may be important. Most patients with chronic heart failure do not receive both agents in adequate doses, and in many instances, patients will take only one drug for an extended period before they receive the second agent. The first initiated treatment (i.e. an ACE inhibitor) is more likely to be up-titrated to its target dose, whereas the second agent (i.e. a β-blocker) is often given in suboptimal doses, if given at all. CIBIS III [2] (the Cardiac Insufficiency Bisoprolol Study III) is the first large, prospective study (n = 1010) to compare beginning treatment with open-label β-blocker (bisoprolol) monotherapy to starting treatment with open-label ACE inhibitor (enalapril) monotherapy for the initial treatment of heart failure. The 2.5-year study was conducted in 128 centres across 18 European countries, plus Australia and Tunisia. Patients had mild to moderate chronic heart failure (NYHA class II or III) and left ventricular ejection fraction ≤35%.
Each monotherapy was administered for 6 months at the following target doses: bisoprolol 10mg once daily or enalapril 10mg twice daily. The mean age of the patient population was 72 years, which is close to the mean age in the general population of chronic heart failure patients in clinical practice (approximately 75 years). In the study, 68.2% of the patients were male. After 6 months, each patient had the other medication added to their current monotherapy and the combination was administered for a further 6 to 24 months. The two strategies were blindly compared with regard to the combined primary endpoint of allcause mortality or hospitalisation and with regard to each of these endpoint components individually.
First treatment with bisoprolol was found to be noninferior to enalapril-first treatment. The results at the end of the trial showed that there were no significant differences between the two treatment strategies with regard to the efficacy or tolerability of the two treatment arms. These results indicate that it may be as safe and efficacious to initiate treatment of chronic heart failure with bisoprolol as with enalapril. Thus, bisoprolol-first treatment does not cause treatment concerns.
The general consensus at this session was that the guidelines for the treatment of patients with chronic heart failure should be altered to reflect the results of the CIBIS III study. It is no longer valid to universally recommend that administration of ACE inhibitors should be the first strategy in the initiation of chronic heart failure treatment. Based on these results, the physician can choose to start chronic heart failure treatment with bisoprolol, a β-blocker.
Preventing Strokes and Myocardial Infarction
Hypertension is the most important preventable cause of premature death in developed countries, and the benefits of antihypertensive drugs for the prevention of cardiovascular mortality and morbidity are well established. For almost two decades, there has been debate over which particular antihypertensive agent should be used to initiate treatment. Normally, the physician must use a combination of two or more antihypertensive agents in order to reach the recommended target blood pressure levels in national and international guidelines.
ASCOT Results Make an Impact
The ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) study [3] [4] [5] [6] was the largest study of hypertension ever conducted in Europe. The study randomised 19 257 patients to this independent investigator-initiated, investigator-led, multicentre, prospective clinical trial. ASCOT compared the newer combination of amlodipine (a calcium channel blocker) and perindopril (an ACE inhibitor) with the older but widely used combination of atenolol (a β-blocker) and bendroflumethiazide (a diuretic). Patients were recruited in the UK, Ireland, and the Nordic countries (Sweden, Norway, Finland, Denmark and Iceland).
The primary objective of ASCOT-Blood Pressure Lowering Arm (ASCOT-BPLA) [3] was to assess and compare the long-term effects of the two combination treatments for the lowering of blood pressure on the combined endpoint of nonfatal myocardial infarction (including so-called silent myocardial infarction) and fatal coronary heart disease.
Patients were eligible for ASCOT-BPLA if they were aged 40-79 years at randomisation and had either untreated hypertension (systolic blood pressure ≥160mm Hg, diastolic blood pressure ≥100mm Hg) or treated hypertension (systolic blood pressure ≥140mm Hg, diastolic blood pressure ≥90mm Hg). In addition, study participants had to have at least three other cardiovascular risk factors.
The sponsor, Pfizer, had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. The ASCOT executive committee had full access to all the data at the end of the study and had final responsibility for the decision to submit for publication.
In October 2004, the independent Data Safety Monitoring Board recommended that the study be halted prematurely. There had been 5.5 years' median follow-up and data accumulated from 106 153 patient-years of observation. The trial was stopped on the grounds that compared with those randomised to the amlodipine-based regimen, those receiving the atenolol-based regimen had significantly higher mortality as well as worse outcomes on several other secondary endpoints.
At the end of the trial, 78% of patients were taking at least two antihypertensive agents, while only 15% of patients were receiving amlodipine alone and 9% of patients were receiving atenolol monotherapy.
The primary endpoint of nonfatal myocardial infarction (including so-called silent myocardial infarction) plus fatal coronary heart disease was nonsignificantly lowered by 10% in those receiving the amlodipine-based regimen compared with those randomised to the atenolol-based regimen. However, there were significant reductions in all of the secondary endpoints (except fatal and nonfatal heart failure) in those patients randomised to the amlodipine-based regimen.
The authors stated that, in terms of reducing the incidence of all types of cardiovascular events and all-cause mortality, the findings of ASCOT-BPLA show that in hypertensive patients at moderate risk of developing cardiovascular events, an antihypertensive drug regimen starting with amlodipine, adding perindopril as required, is better than a regimen starting with atenolol and adding a thiazide diuretic as required.
Management of Cholesterol Using Two Medications
The 2002 World Health Report, [7] published by the World Health Organization, estimated that 1.7 million deaths in the European region are a result of high blood cholesterol levels.
Epidemiological studies and randomised controlled trials support the clinical utility of reducing low-density lipoproteincholesterol (LDL-C) and total cholesterol (TC) to lower the risk of coronary heart disease and all-cause mortality. These interventions significantly reduce the risk of clinical events in patients with coronary heart disease, acute coronary syndromes, and coronary heart disease and other vascular risk factors, such as hypertension.
In Europe, statins are the most common treatment to manage lipid levels. [8] However, it has been estimated that approximately 60% of Europeans do not achieve guideline-recommended cholesterol levels.
Lipid-modifying therapy has increased drug expenditures in many countries. However, undertreatment and failure to achieve cholesterol targets compromise treatment outcomes and are also potentially costly, in both human and financial terms. Analysis of German, French and Swedish databases indicates that consistent attainment of cholesterol targets was associated with significantly lower cardiovascular morbidity and hospitalisation costs. In Sweden, the risk of major cardiovascular events was 24% lower in patients who met their treatment goals. Cardiovascular hospitalisation costs were also significantly lower at 2-3 years among patients who achieved their cholesterol goals as opposed to those who did not.
Poor patient compliance, ineffective lipid-lowering therapies, and/or patient or physician reluctance to increase the dose of lipid-lowering drugs because of safety and tolerability con-cerns have been suggested as possible reasons for so many patients not attaining the recommended lipid levels.
Ezetimibe is a cholesterol absorption inhibitor with a positive benefit-risk profile. Statins reduce cholesterol levels by inhibiting production of cholesterol in the liver and peripheral tissues. Thus, these two classes of drugs modify cholesterol levels by two totally independent mechanisms of action. By co-administering these two classes of drugs, better LDL-cholesterol control is achieved through dual inhibition without requiring an increase in statin doses.
Ezetimibe or placebo was added to ongoing simvastatin treatment in 418 patients in a randomised, double-blind, placebocontrolled comparative study. [9] Ezetimibe 10mg daily coadministered with ongoing simvastatin 10mg or 20mg daily enabled more coronary heart disease patients with hypercholesterolaemia to attain the LDL-C treatment target of ≤2.6 mmol/L (100 mg/dL).
In a similar study, ezetimibe or placebo was added to ongoing atorvastatin treatment in 450 patients in a randomised doubleblind, placebo-controlled comparative study. [10] Ezetimibe 10mg daily co-administered with ongoing atorvastatin 10mg or 20mg daily enabled more coronary heart disease patients with hypercholesterolaemia to attain the LDL-C treatment target of ≤2.6 mmol/L (100 mg/dL).
Consensus on Need to Improve Cholesterol Management
Schering-Plough and Merck Sharp & Dohme sponsored a symposium at the congress entitled 'The Essential Role of Cholesterol Absorption in Lipid Management'. The consensus from the presenters and audience was that clinicians need to improve cholesterol management in their patients. It is possible to reach the desired goals using dual therapy with ezetimibe and statins.
In many countries, a tablet containing both ezetimibe and simvastatin is now available. [10] The fixed-dose combination offers a novel option for the management of primary hypercholesterolaemia in diverse patient populations.
Guidelines for the desired levels of cholesterol are available. Physicians must use all means available to ensure that patients reach those target levels.
